By Nikita Maria Jino, Kumar Tanishk and Jonathan Stempel June 11 (Reuters) - A Chinese biotechnology company sued the U.S. government on Thursday over being placed on a list of businesses from China ...

Large building taking shape off Belmont Street.

Any restriction that stems from the designation could have broader implications because WuXi AppTec helps conduct research and development efforts on behalf of many US drugmakers ...

SAN DIEGO, CA, UNITED STATES, June 10, 2026 /EINPresswire.com/ -- As a global company operating in a highly regulated ...

WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry ...

Designation of Chinese firms fuels investor unease, with markets bracing for potential Fed tightening and unwinding of AI trade Alibaba Group Holding and pharmaceutical contractor WuXi AppTec fell on ...

WuXi Biologics’ two manufacturing facilities in Wuxi receives Brazil ANVISA GMP certification: Wuxi, China Thursday, July 2, 2026, 11:00 Hrs [IST] WuXi Biologic, a leading globa ...

Wuxi AppTec is Asia's largest provider of contract pharmaceutical research, helping drug makers shorten their discovery and ...

WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi - Drug Substance Facility ...

WuXi's bioconjugation spinoff is set to break free onto the Hong Kong Stock Exchange this month, with plans to funnel hundreds of millions of dollars in proceeds back into its Asian manufacturing ...

Photo provided to chinadaily.com.cn] Wuxi, an economic powerhouse in East China's Jiangsu province, officially unveiled its ...